Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18427038 | ANTI-DCLK1 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE THEREOF | January 2024 | June 2025 | Allow | 16 | 0 | 1 | No | No |
| 18412245 | COMPOSITIONS AND METHODS COMPRISING SFRP2 ANTAGONISTS | January 2024 | November 2024 | Allow | 10 | 0 | 0 | No | No |
| 18541600 | COMBINATION THERAPIES FOR TREATING CANCER | December 2023 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18459842 | METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIES | September 2023 | February 2025 | Abandon | 18 | 0 | 0 | No | No |
| 18451990 | TREATMENT OF LAG-3 POSITIVE TUMORS | August 2023 | March 2024 | Allow | 7 | 0 | 0 | No | No |
| 18330844 | USE OF an anti-P-selectin antibody | June 2023 | April 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18301141 | USE OF BAZ1B_K426hy AND POLYCLONAL ANTIBODY THEREOF IN PREPARATION OF PRODUCT FOR TUMOR DETECTION | April 2023 | August 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18161713 | METHODS OF TREATING A TUMOR USING AN ANTI-PD-1 ANTIBODY | January 2023 | January 2024 | Abandon | 12 | 1 | 1 | Yes | No |
| 18069489 | APPROACH FOR TREATMENT OF CANCER VIA IMMUNOMODULATION BY USING TALABOSTAT | December 2022 | October 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17955880 | TREATMENT OF CK8 POSITIVE CANCERS IN RELATION WITH K-RAS GENE STATUS | September 2022 | October 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17885255 | VACCINE COMPRISING EPITOPE OF HEAT SHOCK PROTEIN, AND USE THEREOF | August 2022 | May 2025 | Allow | 34 | 0 | 1 | Yes | No |
| 17870010 | METHODS AND COMPOSITIONS RELATING TO ANTI-PD1 ANTIBODY REAGENTS | July 2022 | May 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17860821 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS | July 2022 | September 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17843412 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS | June 2022 | September 2022 | Allow | 3 | 0 | 0 | No | No |
| 17686238 | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | March 2022 | April 2025 | Allow | 37 | 3 | 1 | Yes | No |
| 17587648 | METHOD FOR SUPPRESSING REGULATORY T CELL INFILTRATION BY CCR4 INHIBITION AND METHOD FOR TREATING CANINE NEOPLASTIC DISEASE | January 2022 | March 2024 | Allow | 26 | 1 | 1 | No | No |
| 17587501 | COMPOSITIONS AND METHODS FOR TREATING CYTOKINE RELEASE SYNDROME | January 2022 | December 2024 | Allow | 34 | 2 | 1 | Yes | Yes |
| 17586676 | LIQUID BIOPSY TO DETECT CANCER EARLY AND SENSITIVELY IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 | January 2022 | July 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17547550 | COMPOSITIONS AND METHODS COMPRISING SFRP2 ANTAGONISTS | December 2021 | August 2023 | Allow | 20 | 0 | 1 | Yes | No |
| 17616134 | HUMANIZED TETRA-SPECIFIC OCTAVALENT ANTIBODY AGAINST CLOSTRIDIUM DIFFICILE TOXIN A AND B | December 2021 | March 2024 | Allow | 28 | 0 | 1 | Yes | No |
| 17613121 | ANTI-TYROSINASE ANTIBODY FOR INHIBITING TYROSINASE AND USE THEREOF | November 2021 | February 2025 | Allow | 39 | 0 | 0 | No | No |
| 17400308 | TARGETING TREATMENT FOR ADAM30 IN PATHOLOGICAL CELLS | August 2021 | February 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17381418 | TREATMENT OF T CELL LYMPHOMA | July 2021 | June 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17053008 | ANTIBODIES TO SARS-CORONAVIRUS (COVID-19) S1 SPIKE PROTEIN | July 2021 | May 2025 | Abandon | 54 | 0 | 1 | No | No |
| 17423370 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER | July 2021 | May 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17421202 | MODULATING BIOMARKERS SUCH AS SPP TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY | July 2021 | March 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17304909 | PERTUZUMAB PLUS TRASTUZUMAB FIXED DOSE COMBINATION | June 2021 | January 2025 | Allow | 43 | 2 | 1 | Yes | Yes |
| 17312368 | NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION | June 2021 | March 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17289623 | TREATMENT METHODS | April 2021 | January 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17237433 | NIDOGEN 1 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET OF HEPATOCELLULAR CARCINOMA, COMPOSITION AND METHODS THEREOF | April 2021 | June 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17287358 | DOSING | April 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17230435 | METHODS FOR NONINVASIVE DETECTION, DIAGNOSIS AND TREATMENT OF DISEASE | April 2021 | June 2025 | Abandon | 50 | 3 | 1 | Yes | No |
| 17226233 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | April 2021 | January 2025 | Allow | 45 | 1 | 1 | No | No |
| 16964133 | B7-H4 ANTIBODIES AND METHODS OF USE THEREOF | March 2021 | December 2024 | Allow | 53 | 1 | 1 | Yes | No |
| 17280493 | RECOMBINANT TYPE I CRISPR-CAS SYSTEM AND USES THEREOF FOR KILLING TARGET CELLS | March 2021 | November 2024 | Allow | 44 | 1 | 1 | No | No |
| 17280436 | RECOMBINANT TYPE I CRISPR-CAS SYSTEM AND USES THEREOF FOR GENOME MODIFICATION AND ALTERATION OF EXPRESSION | March 2021 | November 2024 | Allow | 44 | 1 | 1 | No | No |
| 17271491 | NEOANTIGEN ENGINEERING USING SPLICE MODULATING COMPOUNDS | February 2021 | April 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17271018 | ENPP1 Polypeptides and Methods of Using Same | February 2021 | March 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17264998 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | February 2021 | January 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17156392 | MOLECULAR SPATIAL MAPPING OF METASTATIC TUMOR MICROENVIRONMENT | January 2021 | March 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17148227 | TARGETED DELIVERY OF THE ABRIN-A A-CHAIN TO CANCER CELLS | January 2021 | June 2024 | Abandon | 41 | 2 | 1 | No | No |
| 16973400 | ANTI-HER3 Antibody and uses thereof | December 2020 | January 2023 | Abandon | 25 | 0 | 1 | Yes | No |
| 17103762 | COMPOSITIONS AND METHODS FOR CD20 IMMUNOTHERAPY | November 2020 | July 2023 | Allow | 32 | 0 | 1 | Yes | No |
| 17052553 | COMBINED INHIBITION OF PD-1/PD-L1, TGFB AND DNA-PK FOR THE TREATMENT OF CANCER | November 2020 | August 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17052088 | ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF | October 2020 | August 2024 | Abandon | 45 | 0 | 1 | No | No |
| 16964316 | CYTOKINE FUSION PROTEINS | October 2020 | October 2024 | Allow | 51 | 1 | 1 | Yes | No |
| 17051747 | CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF | October 2020 | September 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 17046998 | COMPOSITIONS AND METHODS FOR TREATING CANCER | October 2020 | March 2023 | Allow | 29 | 1 | 1 | No | No |
| 17045587 | NKG2D CHIMERIC ANTIGEN RECEPTORS | October 2020 | June 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17036075 | MODULATING LACTOGENIC ACTIVITY IN MAMMALIAN CELLS | September 2020 | December 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 17040388 | ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES | September 2020 | February 2024 | Abandon | 41 | 3 | 1 | No | No |
| 17027419 | PERSONALIZED CANCER IMMUNOTHERAPY | September 2020 | February 2025 | Allow | 53 | 3 | 1 | No | No |
| 17019747 | ANTI-CEACAM ANTIBODIES AND USES THEREOF | September 2020 | December 2022 | Allow | 27 | 0 | 1 | Yes | No |
| 16980807 | METHODS FOR REGULATING BREAST CANCERS | September 2020 | June 2023 | Abandon | 33 | 1 | 1 | No | No |
| 16980294 | ANTI-CLAUDIN 18.2 ANTIBODIES | September 2020 | June 2022 | Allow | 21 | 0 | 1 | No | No |
| 16979323 | TREATMENT OF HEAD AND NECK CANCER | September 2020 | June 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 16978976 | A RECOMBINANT PROTEIN COMPRISING A DOUBLE STRANDED RNA BINDING DOMAIN | September 2020 | January 2024 | Abandon | 40 | 3 | 1 | No | No |
| 16977126 | USE OF an anti-P-selectin antibody | September 2020 | June 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16971276 | LIGANDS TO GM-CSF OR GM-CSF-RECEPTOR FOR USE IN TREATMENT OF A HAEMATOLOGIC MALIGNANCY IN A PATIENT HAVING UNDERGONE ALLO-HCT | August 2020 | August 2024 | Abandon | 48 | 1 | 1 | No | No |
| 16997307 | VACCINE COMPRISING EPITOPE OF HEAT SHOCK PROTEIN, AND USE THEREOF | August 2020 | May 2022 | Allow | 21 | 0 | 1 | Yes | No |
| 16966968 | METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIES | August 2020 | March 2025 | Allow | 55 | 4 | 1 | Yes | Yes |
| 16944953 | DOSING REGIMEN FOR AN IDO INHIBITOR | July 2020 | April 2024 | Abandon | 45 | 3 | 1 | No | No |
| 15733398 | PSMD9 INHIBITORS FOR THE TREATMENT OF HEPATIC LIPID DYSREGULATION | July 2020 | May 2024 | Allow | 46 | 1 | 1 | No | No |
| 16957837 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | June 2020 | March 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 16956112 | METHODS BASED ON THE DETECTION OF RAD51 FOCI IN TUMOR CELLS | June 2020 | February 2024 | Allow | 43 | 3 | 1 | Yes | No |
| 16892912 | ANTI-PD-1/CD47 BISPECIFIC ANTIBODY AND APPLICATION THEREOF | June 2020 | January 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 16769567 | ANTI-DCLK1 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE THEREOF | June 2020 | October 2023 | Allow | 41 | 1 | 2 | Yes | No |
| 16890835 | METHOD OF SCORING A SAMPLE COMPRISING TUMOR TISSUE | June 2020 | March 2023 | Allow | 33 | 1 | 1 | No | No |
| 16768431 | TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR TREATING CANCERS | May 2020 | May 2024 | Abandon | 47 | 2 | 1 | Yes | Yes |
| 16765257 | SUICIDE GENE THERAPEUTIC AGENT FOR BRAIN TUMORS USING PLURIPOTENT STEM CELL | May 2020 | June 2024 | Allow | 49 | 1 | 1 | Yes | No |
| 16762877 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | May 2020 | June 2023 | Abandon | 37 | 2 | 0 | No | No |
| 16867125 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | May 2020 | May 2022 | Allow | 25 | 0 | 1 | No | No |
| 16652827 | TUMOR AND METASTASIZING MARKER | April 2020 | September 2024 | Allow | 53 | 3 | 1 | Yes | No |
| 16834981 | MARKER FOR GASTROINTESTINAL TUMORS | March 2020 | May 2022 | Allow | 25 | 1 | 0 | Yes | No |
| 16830810 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | March 2020 | May 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16830585 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone | March 2020 | May 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16830909 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | March 2020 | May 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16830763 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone | March 2020 | May 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16806674 | PATIENT PERSONALIZED CANCER VACCINE | March 2020 | June 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16806664 | METHOD OF MAKING A PERSONALIZED CANCER VACCINE | March 2020 | January 2025 | Abandon | 59 | 5 | 0 | No | No |
| 16639441 | TREATMENT OF CK8 POSITIVE CANCERS IN RELATION WITH K-RAS GENE STATUS | February 2020 | November 2022 | Abandon | 34 | 1 | 1 | No | No |
| 16781017 | Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers | February 2020 | April 2024 | Abandon | 50 | 2 | 1 | No | Yes |
| 16635094 | RAPID TUMORIGENICITY SCREENING SYSTEM | January 2020 | February 2022 | Allow | 25 | 1 | 0 | No | No |
| 16632101 | AN APPLICATION OF EXOSOME TBRII PROTEIN AS A MARKER IN THE PREPARATION OF BREAST CANCER DETECTION KIT | January 2020 | February 2022 | Allow | 25 | 1 | 0 | No | No |
| 16631041 | COMPOSITIONS AND METHODS FOR ENHANCING MACROPHAGE-MEDIATED ANTIBODY GUIDED CANCER CELL OR TUMOR ERADICATION | January 2020 | January 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 16723716 | SOURCE OF ORIGIN DECONVOLUTION BASED ON METHYLATION FRAGMENTS IN CELL-FREE DNA SAMPLES | December 2019 | December 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16716815 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR | December 2019 | March 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16621197 | DIAGNOSTIC, PROGNOSTIC, AND MONITORING METHODS FOR SOLID TUMOR CANCERS | December 2019 | January 2023 | Allow | 38 | 2 | 0 | Yes | No |
| 16617725 | METHODS OF TREATING A TUMOR USING AN ANTI-PD-1 ANTIBODY | November 2019 | May 2022 | Allow | 30 | 2 | 0 | No | No |
| 16617074 | ANTI-DOUBLECORTIN-LIKE KINASE 1 ANTIBODIES AND METHODS OF USE | November 2019 | January 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16617229 | COMBINATION THERAPIES FOR TREATING CANCERS | November 2019 | April 2024 | Allow | 53 | 3 | 1 | Yes | No |
| 16616574 | TREATMENT OF LAG-3 POSITIVE TUMORS | November 2019 | July 2023 | Allow | 44 | 3 | 2 | No | No |
| 16687763 | TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMA | November 2019 | October 2023 | Abandon | 47 | 1 | 1 | No | No |
| 16613673 | METHOD FOR SUPPRESSING REGULATORY T CELL INFILTRATION BY CCR4 INHIBITION AND METHOD FOR TREATING CANINE NEOPLASTIC DISEASE | November 2019 | June 2022 | Abandon | 31 | 1 | 1 | No | No |
| 16612363 | COMBINATION THERAPIES FOR TREATING CANCER | November 2019 | June 2023 | Allow | 43 | 3 | 1 | Yes | No |
| 16611018 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | November 2019 | September 2024 | Allow | 59 | 1 | 1 | Yes | No |
| 16608275 | METHODS AND COMPOSITIONS RELATING TO ANTI-PD1 ANTIBODY REAGENTS | October 2019 | April 2022 | Allow | 30 | 1 | 1 | No | No |
| 16597856 | Optimization of Gene Sequences for Protein Expression | October 2019 | November 2022 | Allow | 37 | 1 | 0 | Yes | No |
| 16499995 | Humanized Anti-TPBG Antibody, Preparation Method Therefor, Conjugate Thereof, and Applications | October 2019 | October 2022 | Allow | 37 | 1 | 1 | Yes | No |
| 16499094 | CANCER STEM CELL | September 2019 | September 2022 | Abandon | 36 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SULLIVAN, DENNIS JOHN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SULLIVAN, DENNIS JOHN works in Art Unit 1642 and has examined 110 patent applications in our dataset. With an allowance rate of 59.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner SULLIVAN, DENNIS JOHN's allowance rate of 59.1% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SULLIVAN, DENNIS JOHN receive 1.45 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SULLIVAN, DENNIS JOHN is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +53.0% benefit to allowance rate for applications examined by SULLIVAN, DENNIS JOHN. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.3% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 92.9% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.